Blueprint Medicines
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$8.27B
-53.1
-1.04
$508.82M
649
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.
Recently from Cashu
Blueprint Medicines Reports Promising Data on AYVAKIT for Indolent Systemic Mastocytosis Treatment
Blueprint Medicines Advances Treatment for Indolent Systemic Mastocytosis Blueprint Medicines, a subsidiary of Sanofi, unveils compelling data regarding its therapy AYVAKIT® (avapritinib) for patients…
Blueprint Medicines Supports Sanofi's Acquisition of Vicebio for Innovative Therapies
Sanofi's Strategic Acquisition of Vicebio: A Focus on Innovative Therapies Sanofi SA's recent acquisition of Vicebio Ltd marks a pivotal moment in the biopharmaceutical landscape, underscoring the com…
Blueprint Medicines Gains from Sanofi's Strategic Vicebio Acquisition in Biotechnology Expansion
Sanofi Strengthens Biotechnology Focus with Vicebio Acquisition Sanofi SA (SNY) makes a strategic move in the biotechnology landscape by acquiring Vicebio Ltd, a privately held firm based in London, U…
Blueprint Medicines Faces Short Selling Surge Amid Market Concerns and Investor Scrutiny
Blueprint Medicines Faces Increased Short Selling Amid Growing Market Concerns Blueprint Medicines experiences a significant rise in short selling activity, reflecting a shift in market sentiment towa…